Pre-clinical and clinical evaluation of solution and soft gelatin capsule formulations for a BCS class 3 compound with atypical physicochemical properties

Journal of Pharmaceutical Sciences

Volumn 93, Issue 9, 2004, Pages 2214-2221

  Ramsay Olocco, Karen ^a   Alexandrova, Ludmila ^a   Nellore, Ranjani ^a   Killion, Robert ^a   Li, Li ^a   Coen, Patricia ^a   Ho, Quynh ^a   Jung, Donald ^a   Rocha, Cynthia ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Absorption enhancer; Bioavailability; Biopharmaceutical Classification System (BCS); Capmul MCM; Efflux pump; Formulation; P glycoprotein; Semi solids; Soft gelatin capsule; Vitamin E TPGS

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENT; ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; BUTYLCRESOL; CAPMUL MCM; CAPMUL PG8; DECANOIC ACID DERIVATIVE; DIACYLGLYCEROL; DRUG; DRUG VEHICLE; FILLER; GELATIN; GLYCOPROTEIN P; MACROGOL; MONOACYLGLYCEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; OCTANOIN; PENETRATION ENHANCING AGENT; PROPYLENEGLYCOL MONOCAPRYLATE; R 1481; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOPHARMACEUTICAL CLASSIFICATION SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG COMPATIBILITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE ABSORPTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MICROPIG; NONHUMAN; NORMAL HUMAN; OVERACTIVE BLADDER; PHASE 1 CLINICAL TRIAL; PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL; SEMISOLID; SOFT GELATIN DRUG CAPSULE; SOLID; SWINE; TIME TO REACH PEAK PLASMA CONCENTRATION;

EID: 4344681422     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20127     Document Type: Article

References (12)

1. Stanley JP. 1986. Soft gelatin capsules. In: Lachman L, Lieberman HA, Kanig JL, editors. Theory and practice of industrial pharmacy, 3rd ed. Philadelphia: Lea & Febiger. pp 398-412.
2. Fromm MF. 2000. P-glycoprotein: A defense mecahnism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38(2):69-74.
3. Bittner B, Guenzi A, Fullhardt P, Auercher G, Gonzalez R, Mountfield R. 2002. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated deriviative of 12-hydroxy-stearic acid. Arzneimittel-Forschung 52(9):684-688.
4. Rege B, Kao J, Polli J. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16(4-5): 237-246.
5. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 16(12): 1812-1817.
6. Wu S, Hopkins W. 1999. Characteristics of D-α-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Tech 23:52-68.
7. Price JC. 2000. Polyethylene glycol. In: Kibbe AH, editor. Handbook of pharmaceutical excipients, 3rd ed. Washington DC: American Pharmaceutical Association, pp 392-398.
8. Product Monograph. 2001. Abitec performance products. Columbus, Ohio: Abitec Corp.
9. Chang T, Benet L, Herbert M. 1996. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297-303.
10. Aungst B. 2000. Intestinal permeation enhancers. J Pharm Sci 89(4):429-442.
11. Dintaman JM, Silverman JA. 1999. Inhibition of p-glycoprotein by D-at-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16: 1550-1556.
12. Wacher VJ, Wong S, Wong HT. 2002. Perppermint oil enhances cyclosporine oral bioavailability in rats: Comparison with D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and ketoconazole. J Pharm Sci 91:77-90.